FDA OKs Treatment for HER2-Negative Breast Cancer with Germline BRCA Mutation

Officials with the FDA have approved talazoparib (Talzenna, Pfizer) for the treatment of HER2-negative locally advanced or metastatic breast cancer with germline BRCA (gBRCA) mutations, according to a press release.  
 
Talazoparib, a poly ADP-ribose polymerase (PARP) inhibitor, is indicated for patients with known deleterious or suspected deleterious gBRCA-mutated breast cancer who are selected for the therapy based on an FDA-approved companion diagnostic.
 
As a dual-mechanism PARP inhibitor, talazoparib both inhibits and traps the PARP enzyme, which may lead to heightened cell death, according to Pfizer. 
 
The approval was based on clinical data from the EMBRACA trial, which included 431 participants with a known deleterious or suspected deleterious gBRCA mutation who have received no more than 3 prior cytotoxic chemotherapy regimens for locally advanced or metastatic disease. Additionally, patients were required to have received treatment with an anthracycline and/or a taxane (unless contraindicated) in the neoadjuvant, adjuvant, and/or metastatic treatment setting.
 
Overall, the trial met its primary endpoint, with an estimated median progression-free survival of 8.6 and 5.6 months in the talazoparib and chemotherapy arms, respectively (HR 0.54; 95% CI: 0.41, 0.71; p<0.0001).
 
The most commonly reported adverse reactions were fatigue, anemia, nausea, neutropenia, headache, thrombocytopenia, vomiting, alopecia, diarrhea, and decreased appetite, according to Pfizer.
 
In addition, the FDA also granted approval to the BRACAnalysis CDx test (Myriad Genetic Laboratories), a companion diagnostic test to identify patients who are eligible for treatment with talazoparib. The approval was based on the efficacy of the test demonstrated in the EMBRACA trial population.
 
According to the release, the recommended talazoparib dose is 1 mg taken as a single oral daily dose, with or without food. The prescribing information for the drug includes warnings and precautions for myelodysplastic syndrome/acute myeloid leukemia, myelosuppression, and embryo-fetal toxicity.
 
References
 
FDA approves talazoparib for gBRCAm HER2-negative locally advanced or metastatic breast cancer [news release]. FDA’s website. https://bit.ly/2COKoeD. Accessed October 16, 2018.
 
Talazoparib Fact Sheet. Pfizer’s website. https://www.pfizer.com/files/news/asco/Talazoparib_Fact_Sheet.pdf. Accessed October 16, 2018.
 


Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 


Most Popular

Related Articles

What considerations should pharmacists keep in mind when treating patients with chronic lymphocytic leukemia?
Bernard Marini, PharmD, BCOP, gives an overview of selecting the most effective, safest, and most cost-effective acute myeloid leukemia treatments for patients.
Top news of the day from across the health care landscape.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$